Overall, the results reinforce the recent observations in the NOR-SWITCH and DANBIO studies. The authors conclude that the long-term clinical profile of SB2 is comparable with infliximab.
Lara C. Pullen, PhD, is a medical writer based in the Chicago area.
ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
Reference
- Smolen JS, Choe JY, Prodanovic N, et al. Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: Results of a randomised, double-blind, Phase III transition study. Ann Rheum Dis. 2017 Oct 17. pii: annrheumdis-2017-211741. doi: 10.1136/annrheumdis-2017-211741. [Epub ahead of print]